Pheochromocytoma Market Report 2026

The pheochromocytoma market size has grown steadily in recent years. It will grow from $3.13 billion in 2025 to $3.24 billion in 2026 at a compound annual growth rate (CAGR) of 3.5%. The growth in the historic period can be attributed to improvements in adrenal tumor diagnosis, availability of surgical treatment options, rising clinical awareness of endocrine tumors, expansion of imaging-based diagnostic tools, increased reporting of hypertension-related conditions.

The pheochromocytoma market size is expected to see steady growth in the next few years. It will grow to $3.87 billion in 2030 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to growing adoption of precision oncology approaches, rising investments in rare tumor research, expansion of genetic screening programs, increasing use of targeted therapies, advancements in radionuclide treatment techniques. Major trends in the forecast period include increasing adoption of advanced imaging diagnostics, rising use of genetic testing for tumor identification, growing preference for minimally invasive surgical treatments, expansion of targeted radionuclide therapies, enhanced focus on early disease detection.

The growing incidence of tumors is expected to drive the growth of the pheochromocytoma market in the coming years. Tumors are abnormal cell growths that may be benign or malignant in nature. The increasing number of tumor and cancer cases highlights the need for greater medical awareness, accurate diagnostic approaches, and customized treatment strategies for the effective management of pheochromocytoma. As a rare adrenal gland tumor, pheochromocytoma contributes to the overall rise in diagnosed endocrine neoplasms, particularly as improved awareness and diagnostic capabilities lead to higher detection rates. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases increased to 1,958,310 in 2023. Therefore, the rising incidence of tumors is contributing to the growth of the pheochromocytoma market.

Major companies operating in the pheochromocytoma market are actively conducting clinical trials to evaluate new treatment methods, therapies, and medications, supporting the development of more effective and targeted treatment options and improving patient outcomes. For example, in May 2025, Merck and Co., a US-based biopharmaceutical company, received approval from the Food and Drug Administration for Welireg (belzutifan), an oral therapy for adult and pediatric patients aged 12 years and older with locally advanced pheochromocytoma or paraganglioma. This therapy targets tumor growth by selectively inhibiting hypoxia-inducible factor 2 alpha, a key molecular driver in many pheochromocytoma and paraganglioma tumors, helping to slow disease progression. In addition, Welireg offers a convenient oral, non-surgical option for the long-term management of advanced disease in eligible patients.

In August 2024, Laboratory Corporation, a US-based healthcare company providing laboratory services, acquired certain assets of Invitae Corporation for an undisclosed amount. Through this acquisition, Laboratory Corporation aims to strengthen its genetic testing capabilities, enhance patient care through advanced diagnostic solutions, and expand its presence in specialty testing. Invitae Corporation is a US-based medical genetics company that offers genetic testing services to identify hereditary syndromes associated with pheochromocytoma.

Major companies operating in the pheochromocytoma market are Pfizer Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Company Limited, Mylan N.V., Bausch Health Companies Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Apotex Inc., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Endo International plc, Exelixis Inc., Lupin Limited, Lantheus Holdings Inc., Curium Pharma, ANI Pharmaceuticals Inc., Jubilant Cadista Pharmaceuticals Inc., WellSpring Pharmaceutical Corporation, HRA Pharma SE.

North America was the largest region in the pheochromocytoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pheochromocytoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pheochromocytoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the pheochromocytoma market by increasing costs of imported imaging equipment, radiopharmaceuticals, surgical instruments, and genetic testing kits used in diagnosis and treatment. Hospitals and diagnostic centers in North America and Europe are most affected due to dependence on imported advanced medical technologies, while Asia-Pacific faces cost pressures related to equipment procurement. These tariffs are raising diagnostic and treatment costs and affecting hospital capital budgets. At the same time, they are encouraging regional manufacturing of diagnostic tools, localized radiopharmaceutical production, and increased investment in domestic oncology research infrastructure.

The pheochromocytoma market research report is one of a series of new reports that provides pheochromocytoma market statistics, including pheochromocytoma industry global market size, regional shares, competitors with a pheochromocytoma market share, detailed pheochromocytoma market segments, market trends and opportunities, and any further data you may need to thrive in the pheochromocytoma industry. This pheochromocytoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pheochromocytoma is a rare tumor that develops in the center of one or both adrenal glands. These tumors originate from cells of the adrenal medulla, which produce hormones such as adrenaline (epinephrine) and noradrenaline (norepinephrine). Excessive secretion of these hormones can occur in pheochromocytoma, leading to symptoms including high blood pressure, rapid heart rate, anxiety, and related effects.

The primary types of pheochromocytoma are adrenal pheochromocytomas and extra-adrenal pheochromocytomas. Adrenal pheochromocytoma is a form that arises within the adrenal glands located above the kidneys and can result in overproduction of hormones such as adrenaline and noradrenaline, causing symptoms such as hypertension and increased heart rate. Treatment options for pheochromocytoma include medication, surgery, radionuclide therapy, and others, while diagnostic approaches involve laboratory tests, imaging tests, and genetic testing. These diagnostic and treatment services are provided by end users such as hospitals, clinics, research and academic institutes, and others.

The pheochromocytoma market consists of revenues earned by entities by providing ablation therapy, embolization therapy and targeted therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The pheochromocytoma market also includes sales of prazosin, terazosin and doxazosin, which are used in providing pheochromocytoma treatment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.